Neuroimmunology of multiple sclerosis and experimental allergic encephalomyelitis.
The potential causes, immunopathology, and treatment of multiple sclerosis (MS) are summarized in this article. Findings from a well-examined animal model for MS, experimental allergic encephalomyelitis (EAE), are described and used to illustrate the paths of research in MS. Data from a recent clinical trial with a modified myelin peptide provide support for concepts deduced from EAE. The authors stress that the complexity of the disease requires new techniques to capture the influence of single or combined treatment approaches.
Stuerzebecher
S
S
Cellular Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disease and Stroke/NIH, 10 Center Drive MSC 1400, Bethesda, MD 20892, USA.
Martin
R
R
D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology; D001324:Autoantigens / Q000276:immunology; D001812:Blood-Brain Barrier / Q000276:immunology; D001921:Brain / Q000276:immunology; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D004676:Myelin Basic Protein / Q000037:antagonists & inhibitors / Q000276:immunology; D009186:Myelin Sheath / Q000276:immunology; D010446:Peptide Fragments / Q000037:antagonists & inhibitors / Q000276:immunology; D011994:Recombinant Proteins / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology
D001324:Autoantigens; D007166:Immunosuppressive Agents; D004676:Myelin Basic Protein; D010446:Peptide Fragments; D011994:Recombinant Proteins; C113463:myelin basic protein 83-102